Fate Therapeutics CEO Scott Wolchko to retire Dec 31; succeeded by Bob Valamehr

FATE THERAPEUTICS INC

Wolchko resigned from board Nov 27, 2024; will retire as President & CEO effective Dec 31, 2024.
Valamehr, currently President of R&D, becomes President & CEO Jan 1, 2025; also named director.
Wolchko to remain a strategic advisor after retirement; resignation not due to any disagreement.
Valamehr has led iPSC platform development ~15 years; oversaw 13 IND applications and pipeline.
FT819 SLE trial: first patient achieved drug-free remission after single dose; no dose-limiting toxicities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.